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Early detection of ovarian cancer through screening may have impact on mortality from the disease. Approaches based on CA125
cut-off have not been effective. Longitudinal algorithms such as the Risk of Ovarian Cancer Algorithm (ROCA) to interpret CA125
have been shown to have higher sensitivity and specificity than a single cut-off.The aimof this studywas to investigatewhether other
ovarian cancer-related biomarkers, Human Epididymis 4 (HE4), glycodelin, mesothelin, matrix metalloproteinase 7 (MMP7), and
cytokeratin 19 fragment (CYFRA 21-1), could improve the performance of CA125 in detecting ovarian cancer earlier. Serum samples
(single and serial) predating diagnosis from 47 women taking part in the UK Collaborative Trial of Ovarian Cancer Screening
(UKCTOCS) who went on to develop primary invasive ovarian, fallopian tube, or peritoneal cancer (index cancer) (170 samples)
and 179 matched controls (893 samples) were included in the study. A multiplex immunobased assay platform (Becton Dickinson)
allowing simultaneous measurement of the six serum markers was used. The area under the ROC curve for the panel of three
biomarkers (CA125, HE4, and glycodelin) was higher than for CA125 alone for all analysed time groups, indicating that these
markers can improve on sensitivity of CA125 alone for ovarian cancer detection.
1. Translational Relevance
Despite progress in ovarian cancer treatment over the last
decade, most cases are detected at a late stage when 5-year
survival is about 46.2%. Early detection is crucial to reducing
mortality from the disease. Although serum CA125, which
is currently the only marker used in clinical practice, has
an encouraging sensitivity for detection of ovarian cancer,
its level is low in early stage disease and becomes elevated
only closer to the late stage. Therefore, there is a need
to identify additional markers/multimarker algorithms that
would improve earlier detection. Previous studies reported
controversial results whether inclusion of HE4 analysis could
improve the early prognosis of ovarian cancer [1, 2], and
some papers also considered approaches to assessing the risk
of epithelial ovarian cancer in women with a pelvic mass
[3, 4]. In this study we demonstrate improved performance
of models which combine CA125 with HE4 and glycodelin in
earlier detection and also provide lead time. These findings
will need to be validated in further independent sets but
may be of value in further work trying to improve screening
algorithms.
2. Introduction
There are over 225,000 new cases of ovarian cancer world-
wide each year with over 125,000 deaths annually from the
disease [5]. Ovarian cancer has a poor prognosis in view of
the advanced stage at diagnosis with over 70% of patients
exhibiting spread beyond the pelvis [6] and lack of specific
symptoms. Currently, ovarian cancer screening is not recom-
mended in the general population due to lack of evidence of
a mortality benefit. Strategies utilising serum cancer antigen
125 (CA125) cut-off of 35U/mLwith transvaginal sonography
(TVS) as a first line test have not been shown to be effective
in reducing the mortality in the Prostate Lung Colorectal and
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Ovarian (PLCO) Cancer screening trial [7]. Data from the
multimodal arm of the UK Collaborative Trial of Ovarian
Cancer Screening (UKCTOCS), which used a time-series
algorithm to interpret serum CA125 (the Risk of Ovarian
Cancer Algorithm (ROCA)) as a first line test followed by
TVS as a second line test, has shown encouraging sensitivity
and specificity of this approach on both the prevalence and
incidence screening [8, 9]. While it is encouraging that 48%
of the cases detected were early-stage cancers, it does raise the
need for improving lead time even when high sensitivity and
specificity are achieved.
Numerous other candidate serum biomarkers have been
reported to improve the performance of CA125 when used in
combination, although most have not been tested in longitu-
dinal samples predating diagnosis. Possibly the best of these
candidates is HE4, which has been shown to complement
CA125 in discriminating ovarian cancer from benign disease
and to aid in earlier detection [10–17]. In a study nested
within PLCO, HE4 was the second best marker after CA125
with a sensitivity of 73% compared to 86% for CA125 [16].
Other serum markers, which include mesothelin [14, 18],
matrix metalloproteinase 7 (MMP7) [11, 16, 19], cytokeratin
19 fragment (CYFRA 21-1) [16, 20], and glycodelin [11, 21],
have shown encouraging performance in ovarian cancer, but
mainly in clinical series. However, many of these may not be
useful as ovarian cancer screening markers as they have been
discovered in samples taken at clinical presentation. More
recently, a design where the markers are evaluated using the
PROBE design [22] has been suggested. We therefore sought
to test the performance of serum CA125, HE4, mesothelin,
MMP7, CYFRA 21-1, and glycodelin in a set of longitudinal
case control samples sourced from UKCTOCS. Given that
these samples predate cancer, they provide a unique resource
for the assessment of early diagnostic markers. Markers were
assessed alone and in combination for their ability to predict
ovarian cancer cases prior to clinical diagnosis.
3. Materials and Methods
3.1. Study Details and Subjects. Between April 2001 and
September 2005, 202,638 postmenopausal women aged 50
to 74 were randomised to UKCTOCS [23]. 50,640 women
were randomised to the multimodal group where women
underwent annual serum CA125 testing interpreted using
the ROCA. According to the risk, women were triaged into
normal, intermediate, and elevated risk, which guided further
triage. All women were flagged by “cancer registries” with
the follow-up used for this study as of March 2012. All
women diagnosed with primary invasive ovarian, fallopian
tube, and peritoneal cancer had their diagnosis confirmed
by independent review of medical notes by the UKCTOCS
Outcomes committee. UKCTOCS will soon report on the
mortality benefit of screening usingROCA.The initial dataset
included 60 cases and 180 controls. However, some data was
later removed as the analysis was focused on Type 1 and
Type 2 invasive cancer cases from the multimodal arm: data
for 13 cases, including 11 borderline cases and 2 cases from
the ultrasound arm, and 1 control, who had withdrawn from
the study, were excluded. Thus, samples from 47 women
who developed primary invasive epithelial ovarian, fallopian
tube, or peritoneal cancer from the multimodal screening
arm were included, of whom 43 were screen detected by
ROCA (screen positive) and 4 were missed by screening
(screen negatives). 24 of these cases had 5 serial samples
each preceding diagnosis, whilst 23 had 1–3 samples each,
giving a total of 170 case samples. Out of the 47 cases, 20
were early stage (FIGO stages I and II), while 27 were late
stage (FIGO stages III and IV). In terms of histology, there
were 31 serous cancers, 1 mucinous, 3 endometrioid, 2 clear
cell, 3 carcinosarcoma, and 7 not specified cancers. Each case
was matched on age at randomisation (within 5 years) and
regional centre to 3 controls (179women), who had no history
of cancer or cancer diagnosis during follow-up. Each control
had 4 to 5 serial samples available, giving a total of 893 control
samples.
3.2. Serum Assays. All serum samples were assayed for
CA125, glycodelin, HE4, mesothelin, MMP7 and CYFRA 21-
1 using a proprietary multiplexed immunoassay based on
Luminex technologywhichwas developed and run by Becton
Dickinson. Assays were run blind to the operator.
3.3. Statistical Analysis. Since cancer progression is known to
be associatedwith the exponential growth ofCA125 and other
biomarkers, all biomarker measurements were modified via
logarithmic transformation, as stated in [24], in the form of
𝑌 = log(𝑍 + 4), where 𝑍 is the value of a particular marker.
Data was processed and explored in R 3.1.1 for Mac OS
software with univariate and graphical analysis. In univariate
analysis, a Mann-Whitney test was performed for each of the
considered markers to test if the difference in distributions
for cases and controls is significantly different. Multimarker
models were generated by logistic regression using three
different sets of biomarker measurements; (i) the last mea-
surement closest to diagnosis, (ii) the last measurement
within 6 months of diagnosis, and (iii) the last measurement
at greater than 6 months before diagnosis. Evaluation of the
performance of eachmodel was based on Receiver Operating
Characteristic (ROC) curve analysis, with determination of
the significance of differences in areas under the curves using
the method of DeLong et al. [25].
4. Results
4.1. Study Subjects. In total, 47 women with primary invasive
epithelial ovarian, fallopian tube, or peritoneal cancer were
included in the study. The stage distribution was 42.5% early
stage for all cases (FIGO stages I and II) (41.9% early stage
of only screen-detected cancers).The serial samples predated
diagnosis of cancer up to 4.83 years, with all final samples/last
measurements taken within 0.75 years of diagnosis. The
overall mean age for cases across their samples was 65.46
years (range 52–77.4 years) and for controls was 63.6 years
(range 50.33–78.83 years). Four cases were not detected by
ROCA.
4.2. Univariate Analysis. Theoutcome of a univariate analysis
of the candidate markers is shown in Table 1. Distributions
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Table 1: Characteristics for different biomarkers from dataset. 𝑃 values are calculated for a two-sample Mann-Whitney test.
Cases Controls
𝑃 value
Median Min Max Median Min Max
CA125 (U/mL) 15 4.27 1767.53 8.7 1.54 728.29 <10−4
Glycodelin (ng/mL) 27.79 2.24 13356.05 13.91 <10−4 4763.97 <10−4
HE4 (pmol/L) 51.66 0.6 2378.08 33.72 <10−4 118.5 <10−4
Mesothelin (nmol/L) 7.12 1.52 44.39 6.27 0.759 17.64 0.001
MMP7 (nmol/L) 2.72 0.37 26.7 2.585 0.359 11.41 0.347
CYFRA 21-1 (ng/mL) 0.07 0 8.83 0.06 <10−4 2.05 0.004
Table 2: Areas under the ROC curve for the six individual markers with 95% confidence intervals using the last measurement for all subjects
(47 case samples, 179 control samples), the last measurement for all subjects within 6months of cancer diagnosis (42 case samples, 179 control
samples), and the last measurement for all subjects at greater than 6 months before diagnosis (42 case samples, 179 control samples).
Marker
Last measurement (average
0.29 years before diagnosis)
Last measurement ≤6 months
before diagnosis
Last measurement >6 months
before diagnosis
AUC 95% CI AUC 95% CI AUC 95% CI
CA125 0.957 0.918–0.997 0.976 0.952–0.999 0.763 0.685–0.842
Glycodelin 0.888 0.828–0.948 0.883 0.816–0.949 0.713 0.62–0.806
HE4 0.881 0.81–0.952 0.869 0.792–0.945 0.653 0.551–0.755
Mesothelin 0.712 0.618–0.807 0.729 0.632–0.825 0.539 0.438–0.64
MMP7 0.589 0.484–0.693 0.625 0.517–0.733 0.554 0.448–0.66
CYFRA 21-1 0.71 0.622–0.797 0.72 0.634–0.805 0.492 0.406–0.61
CA125 + HE4 0.965 0.935–0.995 0.98 0.961–0.999 0.77 0.693–0.848
CA125 + glycodelin + HE4 0.967 0.938–0.996 0.982 0.966–0.998 0.789 0.714–0.865
Table 3: AUC and 95% confidence intervals together with sensitivity level for specificity >0.9 for CA125 alone and the best marker
combination using the last measurement for all subjects. A 𝑃 value is given for comparison of AUCs between the multimarker model and
CA125 alone.
Model AUC 95% CI Diff. in AUCs (𝑃) Sensitivity (specificity >0.9)
CA125 0.957 0.918–0.997 — 0.894
CA125 + HE4 0.965 0.935–0.995 0.008 (0.182) 0.894
CA125 + glycodelin + HE4 0.967 0.938–0.996 0.01 (0.206) 0.915
for all markers apart fromMMP7 were significantly higher in
cases compared to controls. Boxplots show the behaviour of
the markers in 6-month steps in the 2-year period preceding
the last measurement, that is, that taken closest to diagnosis,
where the average time to diagnosis was 0.29 years (Figure 1).
In order to obtain biomarker levels at certain time points,
linear interpolation was used during the construction of
boxplots. Each number on the 𝑥-axis in Figure 1 corresponds
to both the red and blue boxplots, which represent dis-
tributions of cases and controls measurements. The figure
demonstrates that CA125, glycodelin, andHE4 providemuch
better discrimination of cases and controls than mesothelin,
MMP7, or CYFRA 21-1. Areas under the ROC curve were
calculated for each marker using the last measurement for all
subjects (Table 2 and Figure 2). CA125 had the highest area
under theROCcurve (0.957)with glycodelin andHE4having
AUCs of >0.88.
4.3. Multivariate Analysis. Although CA125 had the highest
sensitivity for detection of ovarian cancer compared with
the other markers, we tested if combined marker models
could improve on classification performance compared to
CA125 alone. The results are presented in Tables 2 and 3 and
Figure 3. The curves presented in Figure 3 were smoothed
using linear interpolation. Classification performance of all
markers and combinations increased in the lead up to diag-
nosis, but combinations were superior to using CA125 alone
for all time groups preceding diagnosis. A model combining
CA125, glycodelin, and HE4 gave an area under the ROC
curve of 0.967 versus 0.957 for CA125 alone using the last
measurement before diagnosis, although the increase failed
significance using a threshold of 𝑃 = 0.05 (Table 3).TheAUC
using samples taken>6months fromdiagnosiswas 0.789.The
Mann-Whitney test was also performed to check if there is
significant difference in distributions of screen negative cases
and controls for glycodelin, HE4, and their combination.The
results showed that only a difference in HE4 was significant
(𝑃 = 0.009), while glycodelin (𝑃 = 0.09) and multimarker
combination (𝑃 = 0.128) appeared not to be useful in picking
up screen negatives.
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Figure 1: Boxplots for distributions of the values of markers in 6-month time blocks in the 2 years preceding time of last sample taken, that
is, that taken closest to diagnosis. Red boxes are cases and blue boxes are controls.
5. Discussion
This paper reports on the performance of six ovarian cancer
biomarkers, measured using a multiplex immunoassay, in a
set of longitudinal prediagnosis case control serum samples
sourced fromUKCTOCS.We show that whilst 5 of themark-
ers significantly discriminate ovarian cancer cases from con-
trols at the point of last measurement prior to diagnosis, only
3 (CA125, glycodelin, and HE4) demonstrate potential for
earlier diagnosis.Thiswas reflected in the dynamics of change
in time for these markers in individual cases. Combining
these additional markers with CA125 improved classification
performance, although the result was not significantly higher
than for CA125 alone. Lack of significance of the difference
could be explained by the fact that only 4 patients not detected
by ROCA (in UKCTOCS) were included in this study set and
future work would need to assess the performance of these
markers in a more representative cohort containing ∼15%
ROCA-negative cases.
We show that, in addition to HE4 (which has been shown
to be the second best performing marker after CA125 in the
context of screening), glycodelin is a novel and useful adjunct
to CA125 for early detection of ovarian cancer. Glycodelin
has only been previously tested in the diagnosed case control
setting [11, 21], although with promising results. This work
also supports previous studies showing the potential of HE4
[10–14, 16, 19], whilst suggesting that mesothelin, MMP7, and
CYFRA 21-1 are not useful markers for the early detection
of ovarian cancer. The next step in this work would be to
validate these findings in a larger independent set and to test
the potential of these candidates in multimarker longitudinal
algorithms.
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Figure 2: ROC curves for CA125, glycodelin, and HE4 and separately for mesothelin, MMP7, and CYFRA 21-1.
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Figure 3: Area under the ROC curve versus time to diagno-
sis (linearly imputed between real measurements). The 3-marker
combination (CA125, glycodelin, and HE4) consistently improves
performance over CA125 alone out to 18 months prior to diagnosis.
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